HC Wainwright Issues Positive Outlook for RAPT Earnings

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Equities research analysts at HC Wainwright increased their Q1 2025 earnings estimates for RAPT Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.16) per share for the quarter, up from their prior forecast of ($0.63). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.76) EPS.

Several other equities research analysts have also recently weighed in on RAPT. Wells Fargo & Company reduced their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Stifel Nicolaus restated a “hold” rating and set a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.29.

RAPT Therapeutics Stock Performance

NASDAQ RAPT opened at $1.14 on Wednesday. The firm has a 50-day simple moving average of $1.23 and a 200 day simple moving average of $1.53. RAPT Therapeutics has a twelve month low of $0.79 and a twelve month high of $9.65. The stock has a market cap of $39.85 million, a PE ratio of -0.41 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69).

Institutional Trading of RAPT Therapeutics

Several hedge funds have recently modified their holdings of RAPT. Medicxi Ventures Management Jersey Ltd acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $35,316,000. TCG Crossover Management LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $19,751,000. Orbimed Advisors LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $19,750,000. Finally, RTW Investments LP acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $18,587,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.